Comparative Pharmacology
Head-to-head clinical analysis: AXID AR versus ZANTAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXID AR versus ZANTAC.
AXID AR vs ZANTAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nizatidine is a competitive, reversible inhibitor of histamine at the H2-receptors of the gastric parietal cells, reducing gastric acid secretion.
Competitive antagonist of histamine at H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
75 mg orally once daily at bedtime for heartburn relief; maximum 150 mg per 24 hours.
150 mg orally twice daily or 50 mg intravenously every 6-8 hours. Alternatively, 300 mg orally at bedtime.
None Documented
None Documented
Terminal elimination half-life is 1.5–2.5 hours (mean ~2 hours) in patients with normal renal function. In elderly or those with creatinine clearance <50 mL/min, half-life may extend to 4–6 hours, necessitating dose adjustment.
2.5-3 hours (normal renal function); prolonged to 4-5 hours in elderly and up to 20 hours in severe renal impairment (CrCl < 30 mL/min).
Primarily renal; ~60% of an oral dose is excreted unchanged in urine via tubular secretion and glomerular filtration. Hepatic metabolism accounts for ~30% (N-oxidation, S-oxidation, and N-demethylation), with metabolites and small amounts of parent drug eliminated in feces via bile.
Renal: 30% unchanged (tubular secretion); hepatic metabolism to N-oxide, S-oxide, and desmethyl ranitidine; biliary/fecal: minimal.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist